This is the cached copy of http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm227049.htm.

Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links

U.S. Department of Health and Human Services

FDA, U.S. Food and Drug Administration

U.S. Food & Drug Administration

Most Popular Searches

Advisory Committees

Section Contents Menu

Committees & Meeting Materials

Drugs

Endocrinologic and Metabolic Drugs Advisory Committee

-

Slides for the July 15, 2010 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance

FDA

FDA Core Presentations, QNEXA (phentermine/topiramate) Controlled Release Capsules, for the July 15, 2010 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (PDF – 964KB)

VIVUS, Inc

VIVUS Core Presentations, QNEXA (phentermine/topiramate) Controlled Release Capsules, for the July 15, 2010 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (PDF – 3.4MB)

VIVUS Backup Presentations, QNEXA (phentermine/topiramate) Controlled Release Capsules, for the July 15, 2010 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (PDF – 1.1MB)

Open Public Hearing

OPH Core Presentations, QNEXA (phentermine/topiramate) Controlled Release Capsules, for the July 15, 2010 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (PDF – 186KB)

-

-

Page Last Updated: 09/23/2010
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.

FDA

U.S. Food and Drug Administration

10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
Email FDA

U.S. Department of Health &
Human Services

Links on this page: